scholarly journals Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells

2013 ◽  
Vol 31 (2) ◽  
pp. 771-780 ◽  
Author(s):  
YEN TA HUANG ◽  
CHUAN CHU CHENG ◽  
TZU CHUN LIN ◽  
TED H. CHIU ◽  
PEI CHUN LAI
Keyword(s):  
Urothelial Carcinoma ◽  
Therapeutic Potential ◽  
Carcinoma Cells ◽  
Sepantronium Bromide

scholarly journals The inhibitory effect of silencing CDCA3 on migration and proliferation in bladder urothelial carcinoma

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Dexin Shen ◽  
Yayun Fang ◽  
Fenfang Zhou ◽  
Zhao Deng ◽  
Kaiyu Qian ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Urothelial Carcinoma ◽  
Carcinoma Cells ◽  
Expression Level ◽  
Tumor Cell Growth ◽  
Migration Ability ◽  
Bladder Urothelial Carcinoma ◽  
Related Proteins

Abstract Background CDCA3 is an important component of the E3 ligase complex with SKP1 and CUL1, which could regulate the progress of cell mitosis. CDCA3 has been widely identified as a proto-oncogene in multiple human cancers, however, its role in promoting human bladder urothelial carcinoma has not been fully elucidated. Methods Bioinformatic methods were used to analyze the expression level of CDCA3 in human bladder urothelial carcinoma tissues and the relationship between its expression level and key clinical characteristics. In vitro studies were performed to validate the specific functions of CDCA3 in regulating cell proliferation, cell migration and cell cycle process. Alterations of related proteins was investigated by western blot assays. In vivo studies were constructed to validate whether silencing CDCA3 could inhibit the proliferation rate in mice model. Results Bioinformatic analysis revealed that CDCA3 was significantly up-regulated in bladder urothelial carcinoma samples and was related to key clinical characteristics, such as tumor grade and metastasis. Moreover, patients who had higher expression level of CDCA3 tend to show a shorter life span. In vitro studies revealed that silencing CDCA3 could impair the migration ability of tumor cells via down-regulating EMT-related proteins such as MMP9 and Vimentin and inhibit tumor cell growth via arresting cells in the G1 cell cycle phase through regulating cell cycle related proteins like p21. In vivo study confirmed that silencing CDCA3 could inhibit the proliferation of bladder urothelial carcinoma cells. Conclusions CDCA3 is an important oncogene that could strengthen the migration ability of bladder urothelial carcinoma cells and accelerate tumor cell growth via regulating cell cycle progress and is a potential biomarker of bladder urothelial carcinoma.

scholarly journals Nested variant of urothelial carcinoma of the urinary bladder

Rare Tumors ◽  
2011 ◽  
Vol 3 (4) ◽  
pp. 132-134 ◽  
Author(s):  
Tadashi Terada
Keyword(s):  
Urothelial Carcinoma ◽  
Lamina Propria ◽  
Bladder Tumor ◽  
Clinical Course ◽  
Carcinoma Cells ◽  
Ki 67 ◽  
Atypical Cells ◽  
Nested Variant ◽  
Aggressive Clinical Course ◽  
Nephrogenic Metaplasia

The nested variant of urothelial carcinoma (NVUC) is characterized by the presence of benign-appearing urothelial carcinoma cells in the lamina propria, sparing the surface urothelial involvement. NVUC shows aggressive clinical course despite of benign-looking histology. Herein reported are two cases of NVUC. One is 80-year-old woman, and another is 78-year-old man. In both cases, atypical cells forming nests and tubules were seen in the lamina propria without surface urothelial involvement. One case resembled nephrogenic metaplasia and another proliferated Brunn's nest or inverted papilloma. Immunohistochemically, both cases showed positive p53 and high Ki67 labeling, suggesting that both cases are malignant. Immunohistochemically, one case was characterized by positive cytokeratins, EMA, p53, Ki-67 (labeling=15%), α-methylacyl CoA racemase, CA19-9, and MUC1, and another case by positive cytokeratins, EMA, p63, p53, Ki-67 (lebeling=30%), CD10, CEA, and MUC1. Cyto keratin immunoprofiles were described and other antigens’ expressions were shown. The patients are now free of tumor 6 and 15 months after the resection of the bladder tumor.

scholarly journals Anti-proliferative role of recombinant lethal toxin of Bacillus anthracis on primary mammary ductal carcinoma cells revealing its therapeutic potential

Oncotarget ◽  
2017 ◽  
Vol 8 (22) ◽  
pp. 35835-35847 ◽  
Author(s):  
Rekha Khandia ◽  
Bramhadev Pattnaik ◽  
Katherukamem Rajukumar ◽  
Atul Pateriya ◽  
Sandeep Bhatia ◽  
...  
Keyword(s):  
Bacillus Anthracis ◽  
Ductal Carcinoma ◽  
Therapeutic Potential ◽  
Lethal Toxin ◽  
Carcinoma Cells ◽  
Mammary Ductal Carcinoma

scholarly journals Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells

2020 ◽  
Vol 98 (4) ◽  
pp. 355-367 ◽  
Author(s):  
Alessandro Nini ◽  
Michèle Janine Hoffmann ◽  
Rita Lampignano ◽  
Robert große Siemer ◽  
Guus Dalum ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Carcinoma Cells ◽  
Her2 Expression

THE EFFECTS OF PHYSIOLOGIC ESTROGEN CONCENTRATIONS ON THE BCG-INDUCED IMMUNE RESPONSE IN HUMAN UROTHELIAL CARCINOMA CELLS

2009 ◽  
Vol 181 (4S) ◽  
pp. 411-411
Author(s):  
Fanghong Chen ◽  
Amy Guise ◽  
Guangjian Zhang ◽  
William A See
Keyword(s):  
Immune Response ◽  
Urothelial Carcinoma ◽  
Carcinoma Cells

scholarly journals Targeted siRNA Nanoparticles for Mammary Carcinoma Therapy

Cancers ◽  
2019 ◽  
Vol 11 (4) ◽  
pp. 442 ◽  
Author(s):  
Meital Ben-David-Naim ◽  
Arie Dagan ◽  
Etty Grad ◽  
Gil Aizik ◽  
Mirjam Nordling-David ◽  
...  
Keyword(s):  
Mammary Carcinoma ◽  
Therapeutic Potential ◽  
Density Lipoprotein ◽  
Double Emulsion ◽  
Significant Inhibition ◽  
Carcinoma Cells ◽  
Mrna Levels ◽  
Primary Mammary Tumor ◽  
Mammary Carcinoma Cells ◽  
Tumor Accumulation

Non-viral, polymeric-based, siRNA nanoparticles (NPs) have been proposed as promising gene delivery systems. Encapsulating siRNA in targeted NPs could confer improved biological stability, extended half-life, enhanced permeability, effective tumor accumulation, and therapy. In this work, a peptide derived from apolipoprotein B100 (ApoB-P), the protein moiety of low-density lipoprotein, was used to target siRNA-loaded PEGylated NPs to the extracellular matrix/proteoglycans (ECM/PGs) of a mammary carcinoma tumor. siRNA against osteopontin (siOPN), a protein involved in breast cancer development and progression, was encapsulated into PEGylated poly(d,l-lactic-co-glycolic acid) (PLGA) NPs using the double emulsion solvent diffusion technique. The NPs obtained possessed desired physicochemical properties including ~200 nm size, a neutral surface charge, and high siOPN loading of ~5 µg/mg. ApoB-P-targeted NPs exhibited both enhanced binding to isolated ECM and internalization by MDA-MB-231 human mammary carcinoma cells, in comparison to non-targeted NPs. Increased accumulation of the targeted NPs was achieved in the primary mammary tumor of mice xenografted with MDA-MB-231 mammary carcinoma cells as well as in the lungs, one of the main sites affected by metastases. siOPN NPs treatment resulted in significant inhibition of tumor growth (similar bioactivity of both formulations), accompanied with significant reduction of OPN mRNA levels (~40% knockdown of mRNA levels). We demonstrated that targeted NPs possessed enhanced tumor accumulation with increased therapeutic potential in mice models of mammary carcinoma.

scholarly journals Functionalized Upconversion Nanoparticles for Targeted Labelling of Bladder Cancer Cells

Biomolecules ◽  
2019 ◽  
Vol 9 (12) ◽  
pp. 820 ◽  
Author(s):  
Dmitry Polikarpov ◽  
Liuen Liang ◽  
Andrew Care ◽  
Anwar Sunna ◽  
Douglas Campbell ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Cancer Cells ◽  
Near Infrared ◽  
Carcinoma Cells ◽  
Infrared Light ◽  
Upconversion Nanoparticles ◽  
Silica Layer ◽  
Bladder Cancer Cells

Bladder cancer is the ninth most common cancer worldwide. Due to a high risk of recurrence and progression of bladder cancer, every patient needs long-term surveillance, which includes regular cystoscopy, sometimes followed by a biopsy of suspicious lesions or resections of recurring tumours. This study addresses the development of novel biohybrid nanocomplexes representing upconversion nanoparticles (UCNP) coupled to antibodies for photoluminescent (PL) detection of bladder cancer cells. Carrying specific antibodies, these nanoconjugates selectively bind to urothelial carcinoma cells and make them visible by emitting visible PL upon excitation with deeply penetrating near-infrared light. UCNP were coated with a silica layer and linked to anti-Glypican-1 antibody MIL38 via silica-specific solid-binding peptide. Conjugates have been shown to specifically attach to urothelial carcinoma cells with high expression of Glypican-1. This result highlights the potential of produced conjugates and conjugation technology for further studies of their application in the tumour detection and fluorescence-guided resection.

scholarly journals Author Correction: Early Cellular Responses of Prostate Carcinoma Cells to Sepantronium Bromide (YM155) Involve Suppression of mTORC1 by AMPK

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
David Danielpour ◽  
Zhaofeng Gao ◽  
Patrick M. Zmina ◽  
Eswar Shankar ◽  
Benjamin C. Shultes ◽  
...  
Keyword(s):  
Prostate Carcinoma ◽  
Cellular Responses ◽  
Carcinoma Cells ◽  
Sepantronium Bromide

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Sign in / Sign up

Export Citation Format

Share Document